Targeting of AhR is of great medical and pharmaceutical interest for inhaled therapies targeting diseases in which immunopathology plays a pathogenetic role
Check out our Vital Shots, targeted for energy, immunity, and skin glow
Both tirzepatide and retatrutide are made by Eli Lilly, and the transition would involve a standard dose titration protocol
10.1155/2015/601985 11 BartnessT
But the rationale is sound: GLP-1 receptors exist on a continuum of activation, and partial activation may produce partial benefits with fewer side effects
Lupus, Sjgrens, and Ankylosing Spondylitis and More GLP-1s may calm immune responses, offset steroid-induced weight gain, protect the kidneys, and lower heart disease risk